Amorfix receives ISO13485 certification
Amorfix Life Sciences announced that it has achieved ISO13485:2003 certification for its in vitro diagnostic EP-vCJDTM test for detection of aggregated misfolded proteins in variant Creutzfeldt-Jacob Disease (vCJD).
"This achievement is a significant step forward in the commercialization of our proprietary EP-vCJD(tm) diagnostic test for screening blood donations," said Dr. George Adams, CEO of Amorfix Life Sciences. "The ISO certification demonstrates we have the processes needed to manufacture and distribute the test to the international quality standards required by customers. We are on schedule to obtain a European Union CE mark and launch our first product in the first quarter of 2008."
ISO13485:2003 is an internationally recognized process-based quality management system standard for medical devices developed by the International Organization for Standardization. ISO13485 specifies requirements for a Quality Management System which demonstrate the organization's ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. The management systems that are essential include staff training, customer and regulatory communication, product design and development, sourcing and purchasing of materials and services, and delivery of products and services.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Zebrafish data supports new drug candidate moving into human clinical trials - Data Form Part of a Successful Safety and Toxicity Filing to the UK's Regulatory Agency MHRA
Acambis starts Phase I trial of C. difficile vaccine in elderly subjects

NMR technique offers 'molecular window' into living organisms
The LifeGene project provides unique insight into the causes of disease
Eisai Licenses Selective Estrogen Receptor Modulators (SERMs) to Radius
VABIOTECH licenses cell-based japanese encephalitis technology from Inviragen
Black sheep: Why some strains of the Epstein Barr virus cause cancer
